[Evolution of techniques for preparation of labile blood products (LBP): pathogen inactivation in LBP]. (Q50452728)

14 March 2018

review article

1 reference

title

[Evolution of techniques for preparation of labile blood products (LBP): pathogen inactivation in LBP]. (English)

1 reference

14 March 2018

author name string

C Naegelen

1

1 reference

14 March 2018

H Isola

2

1 reference

14 March 2018

D Dernis

3

1 reference

14 March 2018

J-P Maurel

4

1 reference

14 March 2018

R Tardivel

5

1 reference

14 March 2018

S Bois

6

1 reference

14 March 2018

C Vignoli

7

1 reference

14 March 2018

J-P Cazenave

8

1 reference

14 March 2018

publication date

13 May 2009

1 reference

14 March 2018

Transfusion Clinique et Biologique

published in

1 reference

14 March 2018

volume

16

1 reference

14 March 2018

issue

2

1 reference

14 March 2018

page(s)

179-189

1 reference

14 March 2018

Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Pathogen inactivation: a new paradigm for blood safety.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Pathogen inactivation: making decisions about new technologies. Report of a consensus conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Safety of the blood supply: role of pathogen reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

The hazards of blood transfusion in historical perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Reducing the infectivity of blood components--what we have learned

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Prevention of transfusion-associated cytomegalovirus infection in very low-birthweight infants using frozen blood and donors seronegative for cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Efficacy of Epstein-Barr virus removal by leukoreduction of red blood cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Effect of gamma irradiation on the human immunodeficiency virus and human coagulation proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Influence of methylene blue photoinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitates and cryosupernatants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

No evidence for neoantigens in human plasma after photochemical virus inactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Filtration of methylene blue-photooxidized plasma: influence on coagulation and cellular contamination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

What's happening? The quality of methylene blue treated FFP and cryo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

The six questions of pathogen reduction technology: an overview of current opinions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Pathogen reduction of blood components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using amotosalen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

Functional characteristics of photochemically treated platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2009.03.022

[Post-transfusional cytomegalovirus infections: incidence and methods of prevention. CMV group of SNTS]

7 January 2021

1 reference

12 December 2020

Use of laser-UV for inactivation of virus in blood products

1 reference

12 December 2020

A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant

1 reference

12 December 2020

Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates

1 reference

12 December 2020

A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system

1 reference

12 December 2020

Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen

1 reference

12 December 2020

10.1016/J.TRACLI.2009.03.022

Identifiers

DOI

1 reference

14 March 2018

1 reference

14 March 2018